바이오테크 보도자료
-
- Takeda Completes Sale of Select OTC and Non-Core Assets to Orifarm
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Orifarm Group (“Orifarm”) for a total value of up to $670 million USD. The po...
- 2021년 04월 01일
-
- Xlife Sciences AG (XLS): 2020 Financial Results
- In 2020, Xlife Sciences AG (XLS) significantly increased its profit to 21.2 million Swiss francs compared to the previous year (1.03 million). The increase is based on the transaction and the capital appreciation of the portfolio companies Velabs ...
- 2021년 04월 01일
-
- Takeda Completes Sale of Its Japan Consumer Health Care Business Unit to Blackstone
- Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of Takeda Consumer Healthcare Company Limited (“TCHC”) to Oscar A-Co KK, a company controlled by funds managed...
- 2021년 04월 01일
-
- Humanigen Announces Pricing of Public Offering of Five Million Shares of Common Stock
- Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that it has price...
- 2021년 04월 01일
-
- Humanigen Announces Proposed Public Offering of Five Million Shares of Common Stock
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumabTM, today announced that it has com...
- 2021년 03월 31일
-
- VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
- Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency (EMA) accepted to review the Marketing Authorization Application (MAA) for difelikefa...
- 2021년 03월 30일
-
- Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced positive topline...
- 2021년 03월 30일
-
- Vifor Pharma to propose Åsa Riisberg for appointment to Board of Directors
- Regulatory News: Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021. Åsa Riisberg, a Swedish citizen, was formerly Partner and member of t...
- 2021년 03월 29일
-
- AOP Orphan reports full validity of arbitral award against PharmaEssentia
- Since 2017, PharmaEssentia had repeatedly attempted to terminate the agreement with AOP Orphan concerning BESREMi® (Ropeginterferon alfa-2b). After two and a half years of arbitral proceedings, in October 2020, the ICC Arbitral Tribunal issued its...
- 2021년 03월 26일
-
- Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated for the...
- 2021년 03월 26일
-
- Alvotech Disputes AbbVie’s Recent Allegations
- Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab). Alvotech will vigorously defend against these allegations. Notably, AbbVie waited over three years from the pu...
- 2021년 03월 26일
-
- Philip Morris International Announces the Nomination of International Executives to Its Board of Directors
- Philip Morris International Inc. (PMI) (NYSE: PM) announced in the 2021 Proxy Statement filed today that its Board of Directors has nominated two new members, Dr. Juan José Daboub and Mr. Shlomo Yanai. Additionally, Mr. Jacek Olczak has been nomin...
- 2021년 03월 26일
-
- Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
- Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are available. In particular, efforts to research potential COVID-19 re...
- 2021년 03월 24일
전시회
